test

Joseph Paul Eder MD

Professor of Medicine (Medical Oncology)

Clinical Interests

Some particular areas of past and present involvement in the development of novel therapeutics include high dose chemotherapy, the modulation/ reversal of drug resistance, growth factors, vaccines, signal transduction pathway inhibitors, cell cycle inhibitors, and the therapeutic use of antiangiogenisis agents. In this area, I have interest in developing pharmacodynamic markers of antiangiogenic effects in the clinic including MRI and PET imaging, circulating endothelial cells, monitoring interstitial fluid pressures and the evaluation of tumor biopsies after therapy. The clinical role of pathways to resistance is an area of interest and I have led clinical trials of HGF/MET inhibitors combined with VEGF-targeted therapies.


Board Certifications

1981
Internal Medicine, Board Certified
1983
Medical Oncology, Board Certified
1984
Hematology (Internal Medicine), Board Certified

Patient Care Locations

joseph_ederfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonC80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Colon Cancer and Colon19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the colon
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
EsophagusC80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, Esophagus, and StomachA RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION

More Clinical Trials...

Edit Profile